Ireland· IE-PA-EU/1/26/2024/001-003
Rhapsido 25 mg film-coated tablets
A remibrutinib product containing remibrutinib, registered in Ireland by Novartis Europharm Limited. The same ATC class is registered in 9 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Remibrutinib is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AA60 (remibrutinib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Remibrutinib · ATC L04AA60
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Switzerlandprice
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Remibrutinib
- Manufacturer
- Novartis Europharm Limited
- Country
- Ireland (IE)
- ATC code
- L04AA60
- ATC class
- Remibrutinib
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/26/2024/001-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Remibrutinib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRHAPSIDONovartis Europharm Limited, Dublin
- SpainRHAPSIDO 25 MG COMPRIMIDOS RECUBIERTOS CON PELICULANovartis Europharm Limited
- FinlandRhapsidoNovartis Europharm Limited
- IcelandRhapsidoNovartis Europharm Limited*
- NetherlandsRhapsido 25 mg filmomhulde tablettenNovartis Europharm Limited
- PolandRhapsidoNovartis Europharm Limited
- BelgiumRhapsido 25 mgNovartis Europharm
- SwedenRhapsido 25 mg Filmdragerad tablettNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rhapsido
- Liechtenstein · Rhapsido
- Norway · Rhapsido
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1344c43e-dfd7-401a-b2b3-6f6090ae78ae GET /v1/drugs/1344c43e-dfd7-401a-b2b3-6f6090ae78ae?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L04AA60"
],
"strength": null,
"pa_number": "EU/1/26/2024/001-003",
"substances": [
"Remibrutinib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "23/04/2026",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about remibrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.